Compare FRHC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FRHC | ABVX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.6B |
| IPO Year | N/A | N/A |
| Metric | FRHC | ABVX |
|---|---|---|
| Price | $133.21 | $113.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $112.83 |
| AVG Volume (30 Days) | 90.9K | ★ 1.4M |
| Earning Date | 11-07-2025 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,563,510,000.00 | $7,073,400.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,722.97 | ★ N/A |
| Revenue Growth | ★ 16.04 | N/A |
| 52 Week Low | $111.85 | $4.77 |
| 52 Week High | $194.01 | $130.25 |
| Indicator | FRHC | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.02 | 54.48 |
| Support Level | $131.00 | $107.06 |
| Resistance Level | $138.27 | $130.25 |
| Average True Range (ATR) | 4.52 | 6.32 |
| MACD | 0.91 | -1.65 |
| Stochastic Oscillator | 20.28 | 32.70 |
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.